medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2022, Number 1

<< Back Next >>

Rev Nefrol Dial Traspl 2022; 42 (1)

Comparison of effects of m-TOR inhibitors and calcineurin inhibitor on SUPAR and ox-LDL levels in renal transplant recipients

Yılmaz B, Yılmaz A, Demet AF, Ersan S, Tanrısev M, Çolak H

Language: English
References: 30
Page: 48-55
PDF size: 247.42 Kb.


ABSTRACT

Introduction: We aimed to investigate the effect of different immunosuppressive regimens on SUPAR and ox-LDL levels which are early markers of inflammation in renal transplant recipients. Methods: A total number of 83 patients were enrolled in our study. While fourty- eight of those were received mTORi, thirty five patients were been receiving CNI. According to the immunosuppressive regimen patients were divided into CNI and m-TORi receving groups and serum SUPAR and ox-LDL levels were measured. Results: Log- SUPAR values were lower in the group receiving m-TORi (3.40 ± 0.1 vs 3.48 ± 0.4, p = 0.010). OxLDL / LDL levels were higher (0.0168 ± 005 vs 0.0132 ± 004, p = 0.009) in the CNI group. In linear regression analysis, a statistically significant relationship was detected between the use of m-TORi and log-SUPAR (β = -0.052, 95% CI [-0.224, -0.012], p = 0.041) . A negative and independent relationship was found between HT and log- SUPAR (β = -0.60, 95% CI--0.112, -0.018], p = 0.0024) and ox-LDL (β = -0.169 [-0.330, -0.008], p = 0.040). Very strong correlation (r = 1.0, p = ‹0.001) and independent relationship (β = 0.321 [0.313,0.330], p = ‹0.001) was detected between ox-LDL and SUPAR. Conclusion: As a result, when compared immunsuppression between m-TORi and CNI, the former was associated with lower SUPAR and oxLDL levels.


REFERENCES

  1. Ojo AO. Cardiovascular complications afterrenal transplantation and their prevention.Transplantation. 2006;82(5):603-11. doi: 10.1097/01.tp.0000235527.81917.fe.

  2. Hernández-Fuentes MP, Lechler RI. Chronic graft loss.Immunological and non-immunological factors. ContribNephrol. 2005;146:54-64. doi: 10.1159/000082065.

  3. Baran DA, Galin ID, Gass AL. Calcineurin inhibitorassociatedearly renal insufficiency in cardiac transplantrecipients: risk factors and strategies for prevention andtreatment. Am J Cardiovasc Drugs. 2004;4(1):21-9. doi:10.2165/00129784-200404010-00003.

  4. Guerra G, Srinivas TR, Meier-Kriesche HU.Calcineurin inhibitor-free immunosuppression inkidney transplantation. Transpl Int. 2007;20(10):813-27. doi: 10.1111/j.1432-2277.2007.00528.x.

  5. Kajiwara M, Masuda S. Role of mTOR inhibitors inkidney disease. Int J Mol Sci. 2016;17(6):975. doi:10.3390/ijms17060975.

  6. Baboolal K. A phase III prospective, randomizedstudy to evaluate concentration-controlled sirolimus(rapamune) with cyclosporine dose minimization orelimination at six months in de novo renal allograftrecipients. Transplantation. 2003;75(8):1404-8. doi:10.1097/01.TP.0000063703.32564.3B.

  7. Budde K, Becker T, Arns W, Sommerer C, ReinkeP, Eisenberger U, Kramer S, et al.; ZEUS StudyInvestigators. Everolimus-based, calcineurininhibitor-free regimen in recipients of de-novo kidneytransplants: an open-label, randomised, controlled trial.Lancet. 2011;377(9768):837-47. doi: 10.1016/S0140-6736(10)62318-5.

  8. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J,Mancini D, Valantine-von Kaeppler HA, et al.; RADB253 Study Group. Everolimus for the preventionof allograft rejection and vasculopathy in cardiactransplantrecipients. N Engl J Med. 2003;349(9):847-58. doi: 10.1056/NEJMoa022171.

  9. Eisen H. Long-term cardiovascular risk intransplantation: insights from the use ofeverolimus in heart transplantation. Nephrol DialTransplant. 2006;21(Suppl 3):iii9-13. Doi: 10.1093/ndt/gfl295.

  10. Desmedt S, Desmedt V, Delanghe JR, SpeeckaertR, Speeckaert MM. The intriguing role of solubleurokinase receptor in inflammatory diseases.Crit Rev Clin Lab Sci. 2017;54(2):117-33. doi:10.1080/10408363.2016.1269310.

  11. Eapen DJ, Manocha P, Ghasemzadeh N, Patel RS,Al Kassem H, Hammadah M, et al. Soluble urokinaseplasminogen activator receptor level is an independentpredictor of the presence and severity of coronary arterydisease and of future adverse events. J Am Heart Assoc.2014;3(5):e001118. doi: 10.1161/JAHA.114.001118.

  12. Lyngbæk S, Marott JL, Sehestedt T, Hansen TW,Olsen MH, Andersen O, et al. Cardiovascular riskprediction in the general population with use ofsuPAR, CRP, and Framingham Risk Score. Int JCardiol. 2013;167(6):2904-11. doi: 10.1016/j.ijcard.2012.07.018.

  13. Vela CG, Cristol JP, Descomps B, Mourad G.Prospective study of lipid disorders in FK506-versus cyclosporine-treated renal transplant patients.Transplant Proc. 2000;32(2):398. doi: 10.1016/s0041-1345(99)00993-8.

  14. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solidorgan transplantation. Transplantation. 1997;63(3):331-8. doi: 10.1097/00007890-199702150-00001.

  15. Shihab FS, Bennett WM, Tanner AM, Andoh TF.Mechanism of fibrosis in experimental tacrolimusnephrotoxicity. Transplantation. 1997;64(12):1829-37.doi: 10.1097/00007890-199712270-00034.

  16. Khanna AK, Pieper GM. NADPH oxidase subunits(NOX-1, p22phox, Rac-1) and tacrolimus-inducednephrotoxicity in a rat renal transplant model. NephrolDial Transplant. 2007;22(2):376-85. doi: 10.1093/ndt/gfl608.

  17. Kurdi A, De Meyer GR, Martinet W. Potentialtherapeutic effects of mTOR inhibition in atherosclerosis.Br J Clin Pharmacol. 2016 Nov;82(5):1267-1279. doi:10.1111/bcp.12820.

  18. 18) Kurdi A, De Meyer GR, Martinet W. Potentialtherapeutic effects of mTOR inhibition inatherosclerosis. Br J Clin Pharmacol. 2016;82(5):1267-79. doi: 10.1111/bcp.12820.

  19. Baetta R, Granata A, Canavesi M, Ferri N, ArnaboldiL, Bellosta S, Pfister P, Corsini A. Everolimus inhibitsmonocyte/macrophage migration in vitro and theiraccumulation in carotid lesions of cholesterol-fedrabbits. J Pharmacol Exp Ther. 2009;328(2):419-25.doi: 10.1124/jpet.108.144147.

  20. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H,Rådegran G, Gude E, et al.; SCHEDULE investigators.Everolimus initiation with early calcineurin inhibitorwithdrawal in de novo heart transplant recipients:three-year results from the randomized SCHEDULEStudy. Am J Transplant. 2016;16(4):1238-47. doi:10.1111/ajt.13588.

  21. Masetti M, Potena L, Nardozza M, PrestinenziP, Taglieri N, Saia F, et al. Differential effect ofeverolimus on progression of early and late cardiacallograft vasculopathy in current clinical practice.Am J Transplant. 2013;13(5):1217-26. doi: 10.1111/ajt.12208.

  22. Cakir U, Alis G, Erturk T, Karayagiz AH,Karabulut U, Berber I. Role of Everolimus oncardiac functions in kidney transplant recipients.Transplant Proc. 2017;49(3):497-500. doi: 10.1016/j.transproceed.2017.02.007.

  23. Lim LM, Kung LF, Kuo MC, Kuo HT. The risk factorsof mTORi-associated posttransplant proteinuria.Transplant Proc. 2018;50(8):2535-8. doi: 10.1016/j.transproceed.2018.03.090.

  24. Alachkar N, Li J, Matar D, Vujjini V, Alasfar S, TracyM, et al. Monitoring suPAR levels in post-kidneytransplant focal segmental glomerulosclerosis treatedwith therapeutic plasma exchange and rituximab.BMC Nephrol. 2018;19(1):361. doi: 10.1186/s12882-018-1177-x.

  25. Wei C, El Hindi S, Li J, Fornoni A, Goes N,Sageshima J, et al. Circulating urokinase receptor as acause of focal segmental glomerulosclerosis. Nat Med.2011;17(8):952-60. doi: 10.1038/nm.2411.

  26. Segarra A, Jatem E, Quiles MT, Arbós MA, OstosH, Valtierra N, et al. Valor diagnóstico de los nivelesséricos del receptor soluble de la uroquinasa enadultos con síndrome nefrótico idiopático. Nefrologia.2014;34(1):46-52. doi: 10.3265/Nefrologia.pre2013.Oct.12256.

  27. Maas RJ, Deegens JK, Wetzels JF. Serum suPAR inpatients with FSGS: trash or treasure? Pediatr Nephrol.2013;28(7):1041-8. doi: 10.1007/s00467-013-2452-5.

  28. Holdaas H, Rostaing L, Serón D, Cole E, ChapmanJ, Fellstrøm B, et al.; ASCERTAIN Investigators.Conversion of long-term kidney transplant recipientsfrom calcineurin inhibitor therapy to everolimus:a randomized, multicenter, 24-month study.Transplantation. 2011;92(4):410-8. doi: 10.1097/TP.0b013e318224c12d.

  29. Paoletti E, Citterio F, Corsini A, Potena L, Rigotti P,Sandrini S, et al.; ENTROPIA Project. Everolimus inkidney transplant recipients at high cardiovascular risk:a narrative review. J Nephrol. 2020;33(1):69-82. doi:10.1007/s40620-019-00609-y.

  30. Kurdi A, Roth L, Van der Veken B, Van Dam D,De Deyn PP, De Doncker M, et al. Everolimusdepletes plaque macrophages, abolishes intraplaqueneovascularization and improves survival in micewith advanced atherosclerosis. Vascul Pharmacol.2019;113:70-6. doi: 10.1016/j.vph.2018.12.004.




2020     |     www.medigraphic.com